Table 4.
Change in management according to three indications for Aβ-PET
| Management | Persistent or progressive unexplained MCI (n = 46) | Possible AD with atypical Clinical features (n = 42) | Young-onset dementia (n = 14) | Overall (n = 102) | p-value (comparison among three indications) |
|---|---|---|---|---|---|
| Change in diagnosis, n(%) | 20 (43.5) | 13 (31.0) | 4 (28.6) | 38 (37.3) | 0.39 |
| Change in medications, n(%) | 19 (41.3) | 15 (35.7) | 5 (35.7) | 39 (38.2) | 0.85 |
| Change in AD-specific medications,a n(%) | 13 (28.3) | 10 (23.8) | 4 (28.6) | 27 (26.5) | 0.88 |
| Change in psychiatric treatments,b n(%) | 12 (26.1) | 10 (23.8) | 4 (28.6) | 26 (25.5) | 0.93 |
| Significant change in management,c n(%) | 29 (63.0) | 24 (57.1) | 8 (57.1) | 61 (59.8) | 0.83 |
| Explanation of results and advice on safety and lifestyles, n(%) | 17 (37.0) | 16 (38.1) | 5 (35.7) | 38 (37.3) | 0.99 |
AD, Alzheimer’s disease; ApoE, apolipoprotein E; MCI, mild cognitive impairment.
Overall changes in cholinesterase inhibitors or memantine; include 21 (increase dosage or newly started medications), 4 (decrease in dosage or stopping medications) and 2 (switching medications).
Overall changes including anti-depressants, antipsychotics, sleeping medications, and anti-epileptics; include 20 (increase dosage or newly started medications), 1 (decrease in dosage or stopping medications) and 5 (switching medications).
Significant change in management includes added new medications, withdrawing medications, additional diagnostic tests, advice on daily living and safety concerns or combination of the above.